TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17134351

Group type: EXPERIMENTAL
Intervention: Disease Management Assistance System (DMAS) with adherence educational session
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (education only)
Number of subjects: 62
Study: 12690586

Group type: EXPERIMENTAL
Intervention: Software search method (All About Outcomes)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Library search method
Number of subjects: 30
Study: 10748808

Group type: EXPERIMENTAL
Intervention: Closed reduction and plaster immobilisation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 90
Study: 9186253

Group type: EXPERIMENTAL
Intervention: Vigabatrin (3,000 mg daily for 4 weeks)
Number of subjects: 13
Study: 8098295

Group type: EXPERIMENTAL
Intervention: Prophylactic fortified procaine penicillin (PPF)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Streptomycin
Number of subjects: 737

Group type: COMPARATOR
Intervention: No antibiotics (Control group)
Number of subjects: 737
Study: 3329110

Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg daily)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Piroxicam (20 mg daily)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Tenoxicam and Piroxicam
Number of subjects: 108
Study: 29685693

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily for 15 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 40
Study: 27130369

Group type: EXPERIMENTAL
Intervention: Dexamethasone implant
Number of subjects: 20

Group type: COMPARATOR
Intervention: VEGF-neutralizing protein
Number of subjects: 20
Study: 24059271

Group type: EXPERIMENTAL
Intervention: Cisplatin with 60% oxygen preconditioning for 2 hours at 48, 24, and 6 hours before Cisplatin administration
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cisplatin only (control group)
Number of subjects: 80
Study: 22453707

Group type: EXPERIMENTAL
Intervention: Link Samahan® (one sachet daily in hot water)
Number of subjects: 956

Group type: COMPARATOR
Intervention: Plain tea (control group)
Number of subjects: 956
Study: 20576800

Group type: EXPERIMENTAL
Intervention: Exposure to movie clips portraying smoking as helping to relax
Number of subjects: 77

Group type: COMPARATOR
Intervention: Exposure to movie clips with no clear motive for smoking
Number of subjects: 77

Group type: COMPARATOR
Intervention: Exposure to social smoking clips
Number of subjects: 77

Group type: COMPARATOR
Intervention: Exposure to rebellious smoking clips
Number of subjects: 77
Study: 18426595

Group type: EXPERIMENTAL
Intervention: IFN beta‐1a, 44 mcg subcutaneously (sc) three times weekly (tiw)
Number of subjects: 553

Group type: COMPARATOR
Intervention: IFN beta‐1a, 30 mcg intramuscularly (im) once weekly (qw)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: IFN beta‐1a, 44 mcg sc tiw
Number of subjects: 553

Group type: COMPARATOR
Intervention: IFN beta‐1a, 30 mcg im qw
Number of subjects: 553
Study: 15937989

Group type: EXPERIMENTAL
Intervention: AU dollars 2 scratch lottery ticket
Number of subjects: 443

Group type: COMPARATOR
Intervention: No incentive (control group)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Reminder mailing
Number of subjects: 443
Study: 12973881

Group type: EXPERIMENTAL
Intervention: Computer generated consumer product information
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Computer generated medication timetable
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 179

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 179
Study: 11037895

Group type: EXPERIMENTAL
Intervention: Diacerein 100 mg/day (50 mg twice daily)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Diacerein 50 mg/day and 150 mg/day
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Diacerein (all dosages)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Diacerein 150 mg/day
Number of subjects: 484

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 484
Study: 8803379

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (IVL) 2 mg/kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (IVL) 5 mg/kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral mexiletine
Number of subjects: 9
Study: 1730902

Group type: EXPERIMENTAL
Intervention: Heat-inactivated anti-HIV antibody-rich plasma (7 transfusions every 2 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Seronegative fresh-frozen plasma
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Heat-inactivated anti-HIV antibody-rich plasma
Number of subjects: 18
Study: 3901217

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (dosages varied: 250 mg four times a day; 500 mg three or four times a day; 1 g three or four times a day)
Number of subjects: 1723

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 1723
Study: 29879593

Group type: EXPERIMENTAL
Intervention: Scalpel debridement of plantar hyperkeratoses
Number of subjects: 98

Group type: COMPARATOR
Intervention: Simulated debridement (Control)
Number of subjects: 98
Study: 26782858

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Balance and Toning (BAT)
Number of subjects: 101
Study: 24873162

Group type: EXPERIMENTAL
Intervention: Transumbilical single-site single-port laparoscopic varicolectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Transumbilical single-site double-port laparoscopic varicolectomy
Number of subjects: 80
Study: 24176458

Group type: EXPERIMENTAL
Intervention: Photodocumentation (PD) plus standard of care
Number of subjects: 468

Group type: COMPARATOR
Intervention: Control (standard care without PD)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Photodocumentation (PD)
Number of subjects: 468
Study: 20395338

Group type: EXPERIMENTAL
Intervention: (99m)Tc-DTPA
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Technegas
Number of subjects: 63
Study: 18495737

Group type: EXPERIMENTAL
Intervention: 800 mg of albendazole daily for 8 days
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 15888509

Group type: EXPERIMENTAL
Intervention: 35% CO2 challenge
Number of subjects: 0
Study: 12560439

Group type: EXPERIMENTAL
Intervention: Salvage three-dimensional conformal radiotherapy (3D‐CRT) alone
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Salvage three-dimensional conformal radiotherapy (3D‐CRT) with neoadjuvant androgen deprivation
Number of subjects: 115
Study: 10836329

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 400 microg x day(-1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 200 microg x day(-1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both BDP and FP
Number of subjects: 23
Study: 8610836

Group type: EXPERIMENTAL
Intervention: Home-based multisystemic therapy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual community services (Control)
Number of subjects: 118
Study: 1750591

Group type: EXPERIMENTAL
Intervention: Protamine titration using the Hemochron system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Empirical dose protocol
Number of subjects: 40
Study: 7024767

Group type: EXPERIMENTAL
Intervention: Cortiron (R)‐Depot (11‐Desoxycorticosteronönanthat)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 30
Study: 31960580

Group type: EXPERIMENTAL
Intervention: Self-testing arm
Number of subjects: 2665

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 2665

Group type: EXPERIMENTAL
Intervention: Self-testing programme overall
Number of subjects: 2665
Study: 30676300

Group type: EXPERIMENTAL
Intervention: Moderate hypofractionation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Support for brachytherapy
Number of subjects: 40
Study: 29199654

Group type: EXPERIMENTAL
Intervention: Radiotherapy and concurrent cisplatin infusion (Group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radiotherapy alone (Group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by concurrent chemoradiotherapy
Number of subjects: 50
Study: 25661296

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy at 90 pulses per minute
Number of subjects: 254

Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy at 60 pulses per minute
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy at 90 pulses per minute for proximal ureteral stones
Number of subjects: 254

Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy at 60 pulses per minute for proximal ureteral stones
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy at 90 pulses per minute for mid ureteral stones
Number of subjects: 254

Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy at 60 pulses per minute for mid ureteral stones
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy at 90 pulses per minute for distal ureteral stones
Number of subjects: 254

Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy at 60 pulses per minute for distal ureteral stones
Number of subjects: 254
Study: 24382482

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination
Number of subjects: 601

Group type: COMPARATOR
Intervention: MCP1 rs1024611 polymorphic variants
Number of subjects: 601
Study: 22991979

Group type: EXPERIMENTAL
Intervention: Proactive multifactorial intervention (PMI) including single-pill amlodipine/atorvastatin (SPAA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proactive multifactorial intervention (PMI)
Number of subjects: 0
Study: 19773619

Group type: EXPERIMENTAL
Intervention: Bone cement augmentation (Group 1, n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No bone cement augmentation (Group 2, n=12)
Number of subjects: 24
Study: 18089874

Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m2 intravenously on day 1 with raltitrexed 3 mg/m2
Number of subjects: 250

Group type: COMPARATOR
Intervention: Cisplatin 80 mg/m2 intravenously on day 1 without raltitrexed
Number of subjects: 250
Study: 15336467

Group type: EXPERIMENTAL
Intervention: Controlled-release oxybutynin (15 mg/d, adjusted in 5 mg/d increments)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Immediate-release oxybutynin (TID)
Number of subjects: 125
Study: 11876710

Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg/day for 2 weeks
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Lansoprazole, 30 mg/day for 2 weeks
Number of subjects: 124

Group type: COMPARATOR
Intervention: Pantoprazole, 40 mg/day for 2 weeks
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Post-drug withdrawal
Number of subjects: 124
Study: 9632571

Group type: EXPERIMENTAL
Intervention: DeALPS-CT-2
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: DeALPS-CT-1
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cellular vaccine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Conjugates and cellular vaccine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Conjugates
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Convalescent sera from cholera patients
Number of subjects: 75
Study: 8075015

Group type: EXPERIMENTAL
Intervention: Use of objects for addition
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Use of counting for addition
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Mental calculations using knowledge of number facts and place value
Number of subjects: 55
Study: 2766908

Group type: EXPERIMENTAL
Intervention: 5 mg cisapride
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg cisapride
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16735

Group type: EXPERIMENTAL
Intervention: Triazolam (Halcion) 0.25 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31894029

Group type: EXPERIMENTAL
Intervention: NAD+ ADP‐ribosyl transferase 1 (NART) agonist (DAG‐structured PKC blockers (GF109203X))
Number of subjects: 120

Group type: COMPARATOR
Intervention: Donepezil (DNP) 10mg daily
Number of subjects: 120
Study: 28489468

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate (BD) ¼ dilution (1.25 mg/dL)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) ¼ dilution
Number of subjects: 83

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate (BD) ½ dilution
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) ½ dilution
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) groups
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate (BD) groups
Number of subjects: 83
Study: 26176973

Group type: EXPERIMENTAL
Intervention: Oxycodone/Acetaminophen (5 mg/325 mg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Codeine/Acetaminophen (30 mg/300 mg)
Number of subjects: 240
Study: 23953101

Group type: EXPERIMENTAL
Intervention: Collagen cross-linking (CXL)
Number of subjects: 24
Study: 21787184

Group type: EXPERIMENTAL
Intervention: Mannitol (MTL) 20% (4 mL/kg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HTS) 7.5% (2 mL/kg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47
Study: 19336262

Group type: EXPERIMENTAL
Intervention: High-dose propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoflurane preconditioning
Number of subjects: 0
Study: 17592080

Group type: EXPERIMENTAL
Intervention: L-arginine (3 g/d)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 15106410

Group type: EXPERIMENTAL
Intervention: omeprasol (40 mg/day) and de‐nol (480 mg/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: omeprasol (40 mg/day)
Number of subjects: 63
Study: 12492641

Group type: EXPERIMENTAL
Intervention: Nutritional recommendations based on evidence from RCT and other studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental studies and descriptive epidemiological approaches
Number of subjects: 0
Study: 9613647

Group type: EXPERIMENTAL
Intervention: Intranasally administered immunoglobulin (mainly immunoglobulin A), nasal spray, twice daily for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo, nasal spray, twice daily for 8 weeks
Number of subjects: 40
Study: 7972192

Group type: EXPERIMENTAL
Intervention: Wool and crepe bandages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elasticated tubular bandage
Number of subjects: 0
Study: 2493372

Group type: EXPERIMENTAL
Intervention: Mouth-piece breathing valve assembly
Number of subjects: 10

Group type: COMPARATOR
Intervention: No breathing apparatus
Number of subjects: 10
Study: 29130749

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (n=31)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n=29)
Number of subjects: 60
Study: 26473751

Group type: EXPERIMENTAL
Intervention: VX-509 100 mg/day
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: VX-509 150 mg/day
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: VX-509 200 mg/day
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: VX-509 100 mg twice daily
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study: 24196971

Group type: EXPERIMENTAL
Intervention: TENS and local injection of cobalamin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TENS with a combination of cobalamin and lidocaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: TENS and local injection of lidocaine
Number of subjects: 90
Study: 23896920

Group type: EXPERIMENTAL
Intervention: Intercessory prayer (IP)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Control group (no intercessory prayer)
Number of subjects: 564
Study: 19838638

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Aminoguanidine
Number of subjects: 2

Group type: COMPARATOR
Intervention: L-alanine
Number of subjects: 2
Study: 17936861

Group type: EXPERIMENTAL
Intervention: 417 kcal beverage with 95% of the calories from long-chain fatty acids
Number of subjects: 12

Group type: COMPARATOR
Intervention: 21 kcal lipid-free control beverage
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lipid beverage in High PYY group
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lipid beverage in Low PYY group
Number of subjects: 12
Study: 16417774

Group type: EXPERIMENTAL
Intervention: Suogudan Granule (SGDG) 6 g orally, thrice a day for 6 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Suogudan Granule (SGDG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fenbid Capsules 0.3 g twice a day and Tripterygium tablet 20 mg thrice a day for 6 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fenbid Capsules and Tripterygium tablet
Number of subjects: 90
Study: 12212584

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 88
Study: 10472214

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 20
Study: 8693438

Group type: EXPERIMENTAL
Intervention: Salmeterol 25 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salmeterol and Formoterol
Number of subjects: 10
Study: 1923078

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 102

Group type: COMPARATOR
Intervention: Amoxicillin‐potassium clavulanate
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Compliant cases
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Noncompliant cases
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ethnic group compliance
Number of subjects: 102
Study: 7026794

Group type: EXPERIMENTAL
Intervention: Relaxation training (progressive muscle relaxation training and guided relaxation imagery instructions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No relaxation training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 0
Study: 30348960

Group type: EXPERIMENTAL
Intervention: ELEV (supine, bed elevated 30 degrees)
Number of subjects: 180

Group type: COMPARATOR
Intervention: FLAT (flat, supine)
Number of subjects: 180
Study: 28403531

Group type: EXPERIMENTAL
Intervention: Extracorporeal rinse group (EcRg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Circulatory rinse group (CRg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 25733639

Group type: EXPERIMENTAL
Intervention: High flavanol (HF) cocoa flavanols (993 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intermediate flavanol (IF) cocoa flavanols (520 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Low flavanol (LF) cocoa flavanols (48 mg)
Number of subjects: 90
Study: 24393375

Group type: EXPERIMENTAL
Intervention: FAIM2-rs7138803 polymorphism (AA vs G-carriers)
Number of subjects: 7161

Group type: EXPERIMENTAL
Intervention: FAIM2-rs7138803 polymorphism (AA vs G-carriers) in type-2 diabetic subjects
Number of subjects: 7161
Study: 23015619

Group type: EXPERIMENTAL
Intervention: LMA-Supreme™
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: i-gel™
Number of subjects: 12
Study: 19440810

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg . kg(‐1)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Succinylcholine 1.5 mg . kg(‐1)
Number of subjects: 184
Study: 17520356

Group type: EXPERIMENTAL
Intervention: Workplace-based Work Hardening (WWH)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Clinic-based Work Hardening (CWH)
Number of subjects: 103
Study: 16283605

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐Hu EPO) 750 U/kg per week subcutaneously from day 5 to 40 and enteral iron supplementation of 2 to 6 mg/kg/d beginning on day 14.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Enteral iron supplementation beginning at the end of the fourth week (control group).
Number of subjects: 93
Study: 12217280

Group type: EXPERIMENTAL
Intervention: Heat-killed Mycobacterium vaccae 1mg plus 0.02 microg Tuberculin protein per 0.1 ml dose
Number of subjects: 92

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 92
Study: 10220125

Group type: EXPERIMENTAL
Intervention: Remoxipride (controlled release)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 205
Study: 7824139

Group type: EXPERIMENTAL
Intervention: SDAT patients (n = 61)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control subjects (n = 61)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Follow-up of SDAT patients (n = 23)
Number of subjects: 61
Study: 2104036

Group type: EXPERIMENTAL
Intervention: Diet 1 (D1, n = 5) - 450‐550 kcal/d, protein at 1.5 g/kg IBW, less than 10 g carbohydrate (CHO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diet 2 (D2, n = 5) - 420 kcal/d formula, providing 70 g (1.2 g/kg IBW) protein and 30 g CHO
Number of subjects: 10
Study: 7467379

Group type: EXPERIMENTAL
Intervention: Droperidol (higher dosage)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Droperidol with thiopental (3 mg/kg)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Droperidol with ketamine
Number of subjects: 581
Study: 31537259

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus Aspirin 100 mg once daily
Number of subjects: 18178

Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily
Number of subjects: 18178
Study: 28993415

Group type: EXPERIMENTAL
Intervention: Monitoring according to IGF-I (n=33)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Monitoring according to GHnadir (n=28)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Surgery group
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 84
Study: 26880251

Group type: EXPERIMENTAL
Intervention: Show Me My Health Plans decision support tool
Number of subjects: 362

Group type: COMPARATOR
Intervention: Usual care condition (healthcare.gov marketplace website)
Number of subjects: 362
Study: 24420962

Group type: EXPERIMENTAL
Intervention: THC/CBD spray
Number of subjects: 303